Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research report sent to investors on Friday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright lowered their target price on shares of Trevena from $9.00 to $5.00 and set a buy rating for the company in a report on Thursday, May 16th.

Trevena Price Performance

Trevena stock traded down $0.02 during midday trading on Friday, reaching $0.40. 37,545 shares of the stock traded hands, compared to its average volume of 61,776. The company has a debt-to-equity ratio of 8.35, a quick ratio of 3.60 and a current ratio of 3.60. The company has a 50-day simple moving average of $0.42 and a two-hundred day simple moving average of $0.55. Trevena has a 12-month low of $0.30 and a 12-month high of $1.35.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.01. The business had revenue of $0.02 million during the quarter. Analysts expect that Trevena will post -1.29 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Trevena stock. Jump Financial LLC bought a new stake in Trevena, Inc. (NASDAQ:TRVN) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned about 0.32% of Trevena at the end of the most recent reporting period. 13.56% of the stock is owned by hedge funds and other institutional investors.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.